抗SARS-CoV-2药物的临床研究进展

Clinical research progress on drugs against SARS-CoV-2

由严重急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)感染导致的新型冠状病毒肺炎(Coronavirus Disease 2019,COVID-19)在全球范围内迅速传播,对公共卫生和世界经济产生了破坏性影响。为减少COVID-19所致疾病负担和公共卫生影响,大量预防和治疗性抗SARS-CoV-2药物正被紧急开发,其中以小分子抗病毒药物和单克隆抗体药物为主。目前中国国家药品监督管理局(National Medical Products Administration,NMPA)或美国食品药品监督管理局(Food and Drug Administration,FDA)已批准的3款小分子药物和3款单克隆抗体药物正在使用,本文对目前已上市的主要抗SARS-CoV-2药物的临床研究进展及其目前所面临的挑战作一综述。

The rapid spread of Coronavirus Disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has had a devastating impact on public health and the global economy.Tremendous efforts had been put on urgent development of prophylactic or therapeutic drugs against SARS-CoV-2,mainly smallmolecule antiviral drugs and monoclonal antibodies,to reduce the impact and burden of COVID-19.Currently,National Medical Products Administration(NMPA)of China or Food and Drug Administration(FDA)of the United States have approved three small-molecule drugs and three monoclonal antibodies for use.This paper reviews the clinical research progress and challenges of the main drugs against SARS-CoV-2 on the market at present.